OCE-Funded Active Extramural Research Projects
The FDA Oncology Center of Excellence is currently seeking applications for RFA-FD-24-038: Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers. Applications are due by April 4, 2024.
The FDA Oncology Center of Excellence is funding the active extramural research projects listed in the table below. Click on the links in the Title column to jump to a brief, plain-language abstract for each project. The table will be updated with additional abstracts as they become available.
OCE uses the following funding mechanisms:
- The BAA program is an FDA-wide funding mechanism that solicits research proposals from external institutions on an annual basis (see FY2024 announcement). FDA experts review BAA proposals in two stages for scientific and technical merit, program relevance, offeror capability and budget. BAA research contracts are awarded for a maximum of 5 years. Investigators should develop budgets suitable to complete the proposed work, but OCE prefers to fund focused pilot projects. Applications are reviewed on a rolling basis.
- The CERSI program consists of cooperative agreements with certain institutions selected through a competitive process. Currently, these institutions are Johns Hopkins, University of Maryland, UCSF-Stanford, Yale–Mayo Clinic, and the University of North Carolina. FDA staff may propose projects with investigators at these universities.